Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 2/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201324 | 1.00 | IRAK4 (0.46) | IRAK4CRHBPCRHR2SMN1; SMN2HRH4 | |
| SCHEMBL30834117 | 0.90 | IRAK4 (0.47) | IRAK4HRH4HRH3MAP4K4 | |
| SCHEMBL27201279 | 0.88 | HRH4 (0.54) | IRAK4HRH4HRH3 | |
| SCHEMBL30834150 | 0.88 | HRH4 (0.54) | IRAK4HRH4HRH3 | |
| SCHEMBL27201461 | 0.87 | HRH4 (0.49) | IRAK4HRH4HRH3 | |
| SCHEMBL30885222 | 0.87 | HRH4 (0.49) | IRAK4HRH4HRH3 | |
| SCHEMBL30834156 | 0.85 | NUDT1 (0.53) | IRAK4HRH4 | |
| SCHEMBL27201285 | 0.85 | NUDT1 (0.53) | IRAK4HRH4 | |
| SCHEMBL30834281 | 0.83 | IRAK4 (0.42) | IRAK4HRH4HRH3 | |
| SCHEMBL27201272 | 0.83 | IRAK4 (0.42) | IRAK4HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | IRAK4 1128/4885CRHBP 3574/4885CRHR2 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.